We assessed the contribution of PARP inhibition to the molecular mechanisms involved in AD progression by focusing on several disease-specific features, including AD-like phenotypes such as locomotor dysfunction, reduced lifespan and epigenetic dysregulation of transposable elements activity. The gene discussed is PARP1; the disease is Alzheimer disease.